Skip to content

The effects of recombinant human brain natriuretic peptide on cardiac biomarkers in patients with acute decompensated heart failure

The effects of recombinant human brain natriuretic peptide on cardiac biomarkers in patients with acute decompensated heart failure

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116781
Enrollment
Unknown
Registered
2026-01-14
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure

Interventions

Control Group:Conventional treatment
Trial Group:Recombinant human brain natriuretic peptide (rhBNP)

Sponsors

Ningdu County People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age range: 18 to 75 years old (inclusive). 2.Fulfill the diagnostic criteria for acute heart failure according to the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024. 3.NYHA Class III to IV (per the New York Heart Association functional classification). 4.Willingness to participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Cardiogenic Shock; 2.(Patients) with other serious diseases and a life expectancy of less than 12 months. 3.Women who are pregnant, breastfeeding, or planning to become pregnant within the next 3 months. 4.Severe renal insufficiency, with an estimated glomerular filtration rate (eGFR) of less than 15 mL/min/1.73 m^2. 5.Major organ dysfunction or failure. 6.History of alcohol or drug abuse. 7.Patients with an anticipated hospital stay of 24 hours or less. 8.Patients with a systolic blood pressure (SBP) of less than 90 mmHg. 9.Patients who are likely to have difficulties with study participation or follow-up (e.g., due to non-compliance or legal incompetence). 10.Allergy to the study drug(s). 11.Participation in another clinical trial within the past month. 12.Patients for whom vasodilators are not suitable, including but not limited to those with: severe valvular stenosis; restrictive or obstructive cardiomyopathy; constrictive pericarditis; cardiac tamponade; or other conditions in which cardiac output is dependent on venous return or where low cardiac filling pressure is suspected. 13.Any other condition that, in the opinion of the investigator, may pose a risk to the patient.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;Comparison of the percentage change from baseline in NT-proBNP levels after 3 days of treatment between the two groups of patients;

Countries

China

Contacts

Public ContactZeng Hui

Ningdu County People's Hospital

15070705960@163.com+86 797 681 6056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026